Publications
Explore peer-reviewed scientific publications related to Alnylam’s licensed medicines in the UK (vutrisiran▼, patisiran, givosiran▼ and lumasiran) and their therapeutic areas.
Information on investigational products or unlicensed indications is not included on this website.
The materials in this section are intended for UK healthcare professionals and include scientific and educational publications. The information contained in these publications was accurate at the time of publication. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
UK healthcare professionals seeking details which cannot not be found below, may contact Alnylam Medical, where enquiries will be handled in accordance with UK Medical Information requirements.
Transthyretin Amyloidosis (ATTR)
Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study
Orphanet Journal of Rare Diseases
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
Acute Hepatic Porphyria (AHP)
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study
Molecular Genetics and Metabolism Reports
Transthyretin Amyloidosis (ATTR)
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension
JAMA Neurology
Transthyretin Amyloidosis (ATTR)
Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement
Orphanet Journal of Rare Diseases
